CN102791708B - Akt活性的抑制剂 - Google Patents
Akt活性的抑制剂 Download PDFInfo
- Publication number
- CN102791708B CN102791708B CN201080059321.9A CN201080059321A CN102791708B CN 102791708 B CN102791708 B CN 102791708B CN 201080059321 A CN201080059321 A CN 201080059321A CN 102791708 B CN102791708 B CN 102791708B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- pyrido
- aminocyclobutyl
- oxazin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JDPQGEMJLYSQOK-UHFFFAOYSA-N CC(C1)C(c2ccccc2)C(c2ccc(C3(CCC3)N)cc2)=NC(OC2)=C1N(CC(F)F)C2=O Chemical compound CC(C1)C(c2ccccc2)C(c2ccc(C3(CCC3)N)cc2)=NC(OC2)=C1N(CC(F)F)C2=O JDPQGEMJLYSQOK-UHFFFAOYSA-N 0.000 description 1
- BCIAGTUEQNAEFU-UHFFFAOYSA-N CCN(C(COc1n2)=O)c1cc(-c1ccccc1)c2Br Chemical compound CCN(C(COc1n2)=O)c1cc(-c1ccccc1)c2Br BCIAGTUEQNAEFU-UHFFFAOYSA-N 0.000 description 1
- QKMMEFSGJHNAFX-UHFFFAOYSA-N CN(C)CCN1c2cc(C3=CCCC=C3)c(-c3ccc(C4(CCC4)N)cc3)nc2OCC1=O Chemical compound CN(C)CCN1c2cc(C3=CCCC=C3)c(-c3ccc(C4(CCC4)N)cc3)nc2OCC1=O QKMMEFSGJHNAFX-UHFFFAOYSA-N 0.000 description 1
- WFNUGBUHLGLXNY-UHFFFAOYSA-N CN1c(cc(-c2c[s]cc2)c(-c2ccc(C3(CCC3)N)cc2)n2)c2OCC1=O Chemical compound CN1c(cc(-c2c[s]cc2)c(-c2ccc(C3(CCC3)N)cc2)n2)c2OCC1=O WFNUGBUHLGLXNY-UHFFFAOYSA-N 0.000 description 1
- DULOJLPCJMCVLG-UHFFFAOYSA-N CN1c(cc(-c2ccc[s]2)c(-c2ccc(C3(CCC3)N)cc2)n2)c2OCC1=O Chemical compound CN1c(cc(-c2ccc[s]2)c(-c2ccc(C3(CCC3)N)cc2)n2)c2OCC1=O DULOJLPCJMCVLG-UHFFFAOYSA-N 0.000 description 1
- JUUVWSHWSDZUCO-SOAUALDESA-N C[C@](C1)(C[C@@]1(c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(OC2)c1N(CC(F)(F)F)C2=O)N)O Chemical compound C[C@](C1)(C[C@@]1(c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(OC2)c1N(CC(F)(F)F)C2=O)N)O JUUVWSHWSDZUCO-SOAUALDESA-N 0.000 description 1
- 0 C[C@](C1)(C[C@]1(*)c(cc1)ccc1-c(nc(c(N1CC2CC2)c2)OCC1=O)c2-c1ccccc1)O Chemical compound C[C@](C1)(C[C@]1(*)c(cc1)ccc1-c(nc(c(N1CC2CC2)c2)OCC1=O)c2-c1ccccc1)O 0.000 description 1
- SLXZMJSSMZWMKD-UHFFFAOYSA-N NC1(CCC1)c(cc1)ccc1-c(nc(c(N1c2cnccc2)c2)OCC1=O)c2-c1ccccc1 Chemical compound NC1(CCC1)c(cc1)ccc1-c(nc(c(N1c2cnccc2)c2)OCC1=O)c2-c1ccccc1 SLXZMJSSMZWMKD-UHFFFAOYSA-N 0.000 description 1
- RXYQCNPHFFOQJV-UHFFFAOYSA-N NC1(CCC1)c(cc1)ccc1-c(nc1OCc2nnc(CO)[n]2-c1c1)c1-c1ccccc1 Chemical compound NC1(CCC1)c(cc1)ccc1-c(nc1OCc2nnc(CO)[n]2-c1c1)c1-c1ccccc1 RXYQCNPHFFOQJV-UHFFFAOYSA-N 0.000 description 1
- IHRVBKPFAKYTOS-VNQRBRPCSA-N N[C@](C1)(C[C@H]1O)c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(OC2)c1N1C2=NNC1O Chemical compound N[C@](C1)(C[C@H]1O)c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(OC2)c1N1C2=NNC1O IHRVBKPFAKYTOS-VNQRBRPCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0922589.7A GB0922589D0 (en) | 2009-12-23 | 2009-12-23 | Pharmaceutical compounds |
| GB0922589.7 | 2009-12-23 | ||
| PCT/GB2010/002329 WO2011077098A1 (en) | 2009-12-23 | 2010-12-23 | Inhibitors of akt activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102791708A CN102791708A (zh) | 2012-11-21 |
| CN102791708B true CN102791708B (zh) | 2016-03-02 |
Family
ID=41716932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080059321.9A Active CN102791708B (zh) | 2009-12-23 | 2010-12-23 | Akt活性的抑制剂 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9221838B2 (https=) |
| EP (1) | EP2516435B8 (https=) |
| JP (1) | JP5923043B2 (https=) |
| KR (1) | KR20140015157A (https=) |
| CN (1) | CN102791708B (https=) |
| AU (1) | AU2010334591C1 (https=) |
| BR (1) | BR112012015677A2 (https=) |
| CA (1) | CA2783340C (https=) |
| CY (1) | CY1115686T1 (https=) |
| DK (1) | DK2516435T3 (https=) |
| ES (1) | ES2503794T3 (https=) |
| GB (1) | GB0922589D0 (https=) |
| IL (1) | IL220153A (https=) |
| MX (1) | MX2012007274A (https=) |
| NZ (1) | NZ600453A (https=) |
| PL (1) | PL2516435T3 (https=) |
| PT (1) | PT2516435E (https=) |
| RU (1) | RU2579513C2 (https=) |
| SG (1) | SG181517A1 (https=) |
| SI (1) | SI2516435T1 (https=) |
| WO (1) | WO2011077098A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201205164D0 (en) | 2012-03-23 | 2012-05-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA2971763A1 (en) * | 2014-12-23 | 2016-06-30 | Bergenbio Asa | Inhibitors of akt kinase |
| CN111943962A (zh) * | 2015-02-27 | 2020-11-17 | 大鹏药品工业株式会社 | 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| US11208478B2 (en) | 2016-08-07 | 2021-12-28 | The Wistar Institute Of Anatomy And Biology | Methods of detecting and treating a tumor expressing pT346 PDK1 |
| PE20200696A1 (es) * | 2017-06-22 | 2020-06-16 | Curadev Pharma Ltd | Moduladores de moleculas pequenas de sting humana |
| KR102917509B1 (ko) | 2017-09-07 | 2026-01-26 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | 특이적 akt3 활성제 및 이의 용도 |
| GB2600384A (en) * | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2025250545A1 (en) * | 2024-05-28 | 2025-12-04 | Alterome Therapeutics, Inc. | Akt1 modulators |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101242834A (zh) * | 2004-12-15 | 2008-08-13 | 默克公司 | Akt活性抑制剂 |
| WO2009148916A1 (en) * | 2008-06-03 | 2009-12-10 | Merck & Co., Inc. | Inhibitors of akt activity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT76853A (en) * | 1994-11-14 | 1997-12-29 | Warner Lambert Co | 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same |
| TWI301760B (en) * | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US8008317B2 (en) * | 2005-06-10 | 2011-08-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activtiy |
| CA2656507C (en) * | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| JP2010512312A (ja) | 2006-12-06 | 2010-04-22 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害剤 |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| US7999107B2 (en) * | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| EP2299825B1 (en) | 2008-06-03 | 2013-07-31 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
-
2009
- 2009-12-23 GB GBGB0922589.7A patent/GB0922589D0/en not_active Ceased
-
2010
- 2010-12-23 ES ES10800980.4T patent/ES2503794T3/es active Active
- 2010-12-23 SG SG2012041232A patent/SG181517A1/en unknown
- 2010-12-23 RU RU2012131115/04A patent/RU2579513C2/ru not_active IP Right Cessation
- 2010-12-23 EP EP10800980.4A patent/EP2516435B8/en active Active
- 2010-12-23 SI SI201030774T patent/SI2516435T1/sl unknown
- 2010-12-23 DK DK10800980.4T patent/DK2516435T3/da active
- 2010-12-23 AU AU2010334591A patent/AU2010334591C1/en not_active Ceased
- 2010-12-23 BR BRBR112012015677-2A patent/BR112012015677A2/pt not_active Application Discontinuation
- 2010-12-23 WO PCT/GB2010/002329 patent/WO2011077098A1/en not_active Ceased
- 2010-12-23 KR KR1020127019033A patent/KR20140015157A/ko not_active Ceased
- 2010-12-23 CA CA2783340A patent/CA2783340C/en not_active Expired - Fee Related
- 2010-12-23 MX MX2012007274A patent/MX2012007274A/es active IP Right Grant
- 2010-12-23 PT PT108009804T patent/PT2516435E/pt unknown
- 2010-12-23 US US13/517,219 patent/US9221838B2/en active Active
- 2010-12-23 JP JP2012545434A patent/JP5923043B2/ja active Active
- 2010-12-23 PL PL10800980T patent/PL2516435T3/pl unknown
- 2010-12-23 NZ NZ600453A patent/NZ600453A/xx not_active IP Right Cessation
- 2010-12-23 CN CN201080059321.9A patent/CN102791708B/zh active Active
-
2012
- 2012-06-04 IL IL220153A patent/IL220153A/en not_active IP Right Cessation
-
2014
- 2014-10-31 CY CY20141100899T patent/CY1115686T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101242834A (zh) * | 2004-12-15 | 2008-08-13 | 默克公司 | Akt活性抑制剂 |
| WO2009148916A1 (en) * | 2008-06-03 | 2009-12-10 | Merck & Co., Inc. | Inhibitors of akt activity |
Non-Patent Citations (1)
| Title |
|---|
| Rapid assembly of diverse and potent allosteric Akt inhibitors;Zhicai Wu et al.;《Bioorganic & Medicinal Chemistry Letters》;20071017;第18卷;2211-2214 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1171013A1 (en) | 2013-03-15 |
| US9221838B2 (en) | 2015-12-29 |
| CY1115686T1 (el) | 2017-01-25 |
| WO2011077098A9 (en) | 2012-04-19 |
| IL220153A0 (en) | 2012-07-31 |
| PT2516435E (pt) | 2014-11-13 |
| CA2783340C (en) | 2015-11-24 |
| RU2012131115A (ru) | 2014-01-27 |
| MX2012007274A (es) | 2012-10-03 |
| EP2516435B1 (en) | 2014-08-06 |
| BR112012015677A2 (pt) | 2015-06-30 |
| CN102791708A (zh) | 2012-11-21 |
| JP2013515710A (ja) | 2013-05-09 |
| AU2010334591B2 (en) | 2014-04-10 |
| SG181517A1 (en) | 2012-07-30 |
| AU2010334591A1 (en) | 2012-06-21 |
| JP5923043B2 (ja) | 2016-05-24 |
| GB0922589D0 (en) | 2010-02-10 |
| CA2783340A1 (en) | 2011-06-30 |
| US20130116243A1 (en) | 2013-05-09 |
| IL220153A (en) | 2015-05-31 |
| WO2011077098A1 (en) | 2011-06-30 |
| PL2516435T3 (pl) | 2015-01-30 |
| NZ600453A (en) | 2013-10-25 |
| EP2516435B8 (en) | 2014-10-15 |
| AU2010334591C1 (en) | 2014-07-31 |
| ES2503794T3 (es) | 2014-10-07 |
| KR20140015157A (ko) | 2014-02-06 |
| SI2516435T1 (sl) | 2014-12-31 |
| RU2579513C2 (ru) | 2016-04-10 |
| DK2516435T3 (da) | 2014-10-13 |
| EP2516435A1 (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102791708B (zh) | Akt活性的抑制剂 | |
| CN105814054B (zh) | 作为tnf活性调节剂的稠合咪唑和吡唑衍生物 | |
| CN105555780B (zh) | Syk抑制剂 | |
| WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
| CN112585139A (zh) | 用作t细胞激活剂的萘啶酮化合物 | |
| JP2020518601A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| CN107207467A (zh) | 作为parg的抑制剂的2,4‑二氧代‑喹唑啉‑6磺酰胺衍生物 | |
| CN117946138A (zh) | 并环含氮化合物、其中间体、制备方法和应用 | |
| CN112409385B (zh) | 氮杂芳基化合物及其应用 | |
| CN105916857A (zh) | 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途 | |
| CN119654315A (zh) | 作为qpctl和qpct抑制剂用于治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1,2,4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物 | |
| CN111936484A (zh) | 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物 | |
| WO2014006554A1 (en) | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
| CN110872296A (zh) | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 | |
| WO2020078402A1 (zh) | 作为TGF-βR1抑制剂的化合物及其应用 | |
| TW201441233A (zh) | 作爲β－分泌酶抑制劑之稠合多環的碸化合物及其使用方法 | |
| TW201602116A (zh) | 作為β－分泌酶抑制劑之橋接二環胺基噻嗪二氧化物化合物及其使用方法 | |
| CN114907350A (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
| WO2022237830A1 (zh) | 一类含氮杂环化合物 | |
| HK1171013B (en) | Inhibitors of akt activity | |
| HK40108764A (zh) | 并环含氮化合物、其中间体、制备方法和应用 | |
| HK40123924A (zh) | 作为qpctl和qpct抑制剂用於治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1，2，4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物 | |
| HK40106266A (zh) | Polo样激酶4抑制剂 | |
| HK40106266B (zh) | Polo样激酶4抑制剂 | |
| TW201444828A (zh) | 可作爲溴區結構域蛋白抑制劑之咔唑化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |